Publication | Closed Access

IMO-8400, a toll-like receptor 7, 8, and 9 antagonist, demonstrates clinical activity in a phase 2a, randomized, placebo-controlled trial in patients with moderate-to-severe plaque psoriasis

InflammationToll-like Receptor 7Anti-inflammatoryAutoimmune DiseaseMedicinePharmacologyClinical TrialsImmunologyInflammatory MarkerClinical DermatologyAutoimmunityPharmacotherapyPhase 2AImmunotherapyPsoriatic ArthritisClinical Activity